InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.135 0.025 (1.18%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,773 Stem Cell Heart Attack Trial-Positive Preclinical Results 14 Nov 2006 9:37AM $1.655 $2.135 risen by 29%
$2,773 Commitments Test Entity - First Quarter Report 30 Oct 2006 10:48AM $1.435 $2.135 risen by 48.78%
$2,773 Major stem cell patent granted in US 18 Oct 2006 9:03AM $1.480 $2.135 risen by 44.26%
$2,773 Investment in Angioblast for Phase II Cardiovascular Trial 21 Sep 2006 11:42AM $1.180 $2.135 risen by 80.93%
$2,773 Heart Function Improves in Stem Cell Trials 19 Sep 2006 10:03AM $1.235 $2.135 risen by 72.87%
$2,773 Preliminary Final Report/Full Year Accounts 13 Sep 2006 6:02PM $1.180 $2.135 risen by 80.93%
$2,773 Stem Cell Bone Repair Trials Produce Outstanding Results 22 Aug 2006 1:32PM $1.340 $2.135 risen by 59.33%
$2,773 Commitments Test Entity - Fourth Quarter Report 27 Jul 2006 10:59AM $1.330 $2.135 risen by 60.53%
$2,773 Locks in next stage of Growth 20 Jul 2006 9:54AM $1.320 $2.135 risen by 61.74%
$2,773 Trading Halt 18 Jul 2006 10:56AM n/a $2.135 n/a
$2,773 Targets major cartilage markets 4 Jul 2006 10:22AM $1.410 $2.135 risen by 51.42%
$2,773 Achieves major milestones/Positive results/Commercialisation 7 Jun 2006 11:04AM $1.630 $2.135 risen by 30.98%
$2,773 Positive results in preclinical trials for heart failure 22 May 2006 10:41AM $1.400 $2.135 risen by 52.50%
$2,773 Significant Progress in Clinical Trials 16 May 2006 9:32AM $1.380 $2.135 risen by 54.71%
$2,773 Commitments Test Entity - Third Quarter Report 28 Apr 2006 4:16PM $1.490 $2.135 risen by 43.29%
$2,773 Positive results confirm spinal fusion as major market 27 Apr 2006 9:42AM $1.600 $2.135 risen by 33.44%
$2,773 First Adult Stem Cells for Long Bone Fracture Patient 3 Apr 2006 11:45AM $1.800 $2.135 risen by 18.61%
$2,773 Next generation drug eluting stent technology 22 Mar 2006 9:48AM $1.690 $2.135 risen by 26.33%
$2,773 Half Yearly Report & Half Year Accounts 13 Mar 2006 12:19PM $1.850 $2.135 risen by 15.41%
$2,773 Pre-Clinical Studies validate universal donor business model 13 Feb 2006 9:16AM $1.645 $2.135 risen by 29.79%
$2,773 Commitments Test Entity - Second Quarter Report 31 Jan 2006 5:02PM $1.290 $2.135 risen by 65.50%
$2,773 Key Australian Adult Stem Cell Patent Granted 17 Jan 2006 11:04AM $1.200 $2.135 risen by 77.92%
$2,773 Australian Government awards $2.7m 21 Dec 2005 9:21AM $1.160 $2.135 risen by 84.05%
$2,773 Adult Stem Cell Heart Trial Update 19 Dec 2005 9:59AM $1.130 $2.135 risen by 88.94%
$2,773 First Patients Recruited for Mesoblast Pilot Clinical Trials 7 Dec 2005 8:40AM $1.080 $2.135 risen by 97.69%

1151 - 1175 of 1188 results

Page 47 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.